A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that [[tamoxifen]], [[raloxifene]], and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects.<ref>{{cite web| url=http://archive.ahrq.gov/news/newsroom/press-releases/2009/brcanmed.html| title=Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects, New Report Says| publisher=U.S. Department of Health & Human Services - Agency for Healthcare Research and Quality| date=September 2009|accessdate=2 June 2014}}</ref>

 

